Ketamine is classified as a Schedule III controlled substance under the U.S. Controlled Substances Act, a dissociative anesthetic in clinical medicine, and an NMDA receptor antagonist in pharmacology. That triple classification reflects a drug with an unusual range of uses, from surgical anesthesia to treating severe depression.
Federal Drug Schedule
The Drug Enforcement Administration placed ketamine into Schedule III on August 12, 1999. Before that date, it was an unscheduled prescription drug. The DEA’s decision rested on three findings: ketamine has abuse potential, but less than Schedule I drugs (like heroin) or Schedule II drugs (like cocaine); it has accepted medical uses in the United States; and abuse may lead to moderate or low physical dependence but high psychological dependence.
Schedule III is the same tier as products containing low-dose codeine, anabolic steroids, and testosterone. Drugs in this category sit in a middle zone. They carry enough risk to warrant controlled-substance restrictions, including limits on prescription refills and record-keeping requirements for pharmacies, but they aren’t subject to the stricter quotas and prescribing rules applied to Schedule II substances like oxycodone or fentanyl.
Pharmacological Class
At the molecular level, ketamine belongs to a chemical family called arylcyclohexylamines. Its structure is built around three connected rings: an aryl ring, a cyclohexyl ring, and an amine ring. Phencyclidine (PCP) belongs to the same chemical family, which is one reason the two drugs share certain dissociative effects, though ketamine is shorter-acting and far more widely used in medicine.
Ketamine’s primary action in the brain is blocking NMDA receptors, which normally respond to glutamate, the brain’s main excitatory signaling molecule. It works as an “open channel blocker,” meaning it slips into the receptor’s ion channel only when that channel is already open, then plugs it. This disrupts normal communication between neurons in ways that produce anesthesia, pain relief, and the characteristic feeling of detachment from one’s body and surroundings. That same NMDA-blocking mechanism appears to drive both its therapeutic effects and its potential for misuse.
Clinical Uses: Anesthetic and Antidepressant
Ketamine was introduced in the 1960s as an anesthetic and has been on the World Health Organization’s List of Essential Medicines since 1984, listed under injectable general anesthetics. It remains widely used in operating rooms and emergency departments, particularly in settings where maintaining a patient’s breathing reflexes is important, since it suppresses consciousness without shutting down respiratory drive the way many other anesthetics do. Veterinary medicine also relies heavily on ketamine for sedation and surgical anesthesia in animals.
Over the past two decades, ketamine has gained a second clinical identity. Researchers discovered it can rapidly reduce symptoms of severe depression, sometimes within hours, a dramatic contrast to conventional antidepressants that typically take weeks to work. The FDA has not approved standard (racemic) ketamine for depression, but it has approved a nasal spray form called esketamine, which uses one of ketamine’s two mirror-image molecules. Esketamine is approved for two specific conditions: treatment-resistant depression in adults (with or without a separate oral antidepressant) and depressive symptoms in adults with major depressive disorder who have active suicidal thoughts or behavior (combined with an oral antidepressant). The nasal spray carries the same Schedule III designation.
Why It Carries Abuse Potential
Ketamine’s Schedule III placement reflects real risks when the drug is used outside medical supervision. At sub-anesthetic doses, it distorts perception of sight and sound and creates a sense of disconnection and loss of control. These hallucinogenic effects typically last 45 to 90 minutes, but impairment of senses, judgment, and coordination can persist for up to 24 hours.
Repeated misuse has been linked to depression, delirium, amnesia, impaired motor function, elevated blood pressure, and in severe cases, life-threatening respiratory problems. Long-term heavy use can also damage the bladder and urinary tract. The psychological pull of the dissociative experience is the main driver of dependence, while physical withdrawal symptoms tend to be less intense than those associated with opioids or alcohol. The Department of Justice has also flagged ketamine as a drug that has been used to incapacitate people for sexual assault, either added to drinks without the victim’s knowledge or offered without explanation of its effects.
How These Classifications Overlap
Ketamine sits at an unusual intersection. Its Schedule III legal status allows doctors to prescribe it, but with controlled-substance oversight. Its pharmacological classification as an NMDA antagonist explains both why it works as an anesthetic and why it shows promise for depression. And its clinical classification is actively expanding, from a decades-old surgical tool to a newer psychiatric treatment, with the esketamine nasal spray representing the first FDA-approved product specifically targeting depression through this mechanism.
If you see ketamine described as a “dissociative anesthetic,” that’s its traditional medical label. If you see it called an “NMDA receptor antagonist,” that’s its mechanism of action. And if you see it listed as “Schedule III, CIII,” that’s its legal standing under federal law. All three labels describe the same molecule from different angles.